These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30354365)

  • 1. Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
    Garcia AM; Nakano SJ; Karimpour-Fard A; Nunley K; Blain-Nelson P; Stafford NM; Stauffer BL; Sucharov CC; Miyamoto SD
    Circ Heart Fail; 2018 Sep; 11(9):e004571. PubMed ID: 30354365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.
    Heilman RP; Lagoski MB; Lee KJ; Taylor JM; Kim GA; Berkelhamer SK; Steinhorn RH; Farrow KN
    Am J Physiol Heart Circ Physiol; 2015 Jun; 308(12):H1575-82. PubMed ID: 25862831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
    Pokreisz P; Vandenwijngaert S; Bito V; Van den Bergh A; Lenaerts I; Busch C; Marsboom G; Gheysens O; Vermeersch P; Biesmans L; Liu X; Gillijns H; Pellens M; Van Lommel A; Buys E; Schoonjans L; Vanhaecke J; Verbeken E; Sipido K; Herijgers P; Bloch KD; Janssens SP
    Circulation; 2009 Jan; 119(3):408-16. PubMed ID: 19139381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of PDE5 in failing and nonfailing human myocardium.
    Shan X; Quaile MP; Monk JK; French B; Cappola TP; Margulies KB
    Circ Heart Fail; 2012 Jan; 5(1):79-86. PubMed ID: 22135403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure.
    Gong W; Duan Q; Cai Z; Chen C; Ni L; Yan M; Wang X; Cianflone K; Wang DW
    Br J Pharmacol; 2013 Dec; 170(7):1396-409. PubMed ID: 24032459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
    Blakeslee WW; Demos-Davies KM; Lemon DD; Lutter KM; Cavasin MA; Payne S; Nunley K; Long CS; McKinsey TA; Miyamoto SD
    Pediatr Res; 2017 Oct; 82(4):642-649. PubMed ID: 28549058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosis-Related Gene Expression in Single Ventricle Heart Disease.
    Nakano SJ; Siomos AK; Garcia AM; Nguyen H; SooHoo M; Galambos C; Nunley K; Stauffer BL; Sucharov CC; Miyamoto SD
    J Pediatr; 2017 Dec; 191():82-90.e2. PubMed ID: 29050751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress regulates left ventricular PDE5 expression in the failing heart.
    Lu Z; Xu X; Hu X; Lee S; Traverse JH; Zhu G; Fassett J; Tao Y; Zhang P; dos Remedios C; Pritzker M; Hall JL; Garry DJ; Chen Y
    Circulation; 2010 Apr; 121(13):1474-83. PubMed ID: 20308615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.
    Zhang M; Koitabashi N; Nagayama T; Rambaran R; Feng N; Takimoto E; Koenke T; O'Rourke B; Champion HC; Crow MT; Kass DA
    Cell Signal; 2008 Dec; 20(12):2231-6. PubMed ID: 18790048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling.
    Vandenwijngaert S; Pokreisz P; Hermans H; Gillijns H; Pellens M; Bax NA; Coppiello G; Oosterlinck W; Balogh A; Papp Z; Bouten CV; Bartunek J; D'hooge J; Luttun A; Verbeken E; Herregods MC; Herijgers P; Bloch KD; Janssens S
    PLoS One; 2013; 8(3):e58841. PubMed ID: 23527037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
    Johnson WB; Katugampola S; Able S; Napier C; Harding SE
    Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of cardiolipin biosynthesis and remodeling in single right ventricle congenital heart disease.
    Garcia AM; McPhaul JC; Sparagna GC; Jeffrey DA; Jonscher R; Patel SS; Sucharov CC; Stauffer BL; Miyamoto SD; Chatfield KC
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H787-H800. PubMed ID: 32056460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.
    Isidori AM; Cornacchione M; Barbagallo F; Di Grazia A; Barrios F; Fassina L; Monaco L; Giannetta E; Gianfrilli D; Garofalo S; Zhang X; Chen X; Xiang YK; Lenzi A; Pellegrini M; Naro F
    Cardiovasc Res; 2015 Jun; 106(3):408-20. PubMed ID: 25852085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
    Zhang M; Takimoto E; Lee DI; Santos CX; Nakamura T; Hsu S; Jiang A; Nagayama T; Bedja D; Yuan Y; Eaton P; Shah AM; Kass DA
    Circulation; 2012 Aug; 126(8):942-51. PubMed ID: 22829024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.
    Kumar P; Francis GS; Tang WH
    Nat Rev Cardiol; 2009 May; 6(5):349-55. PubMed ID: 19377497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.
    Zhang M; Takimoto E; Hsu S; Lee DI; Nagayama T; Danner T; Koitabashi N; Barth AS; Bedja D; Gabrielson KL; Wang Y; Kass DA
    J Am Coll Cardiol; 2010 Dec; 56(24):2021-30. PubMed ID: 20970280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pressure Overload Greatly Promotes Neonatal Right Ventricular Cardiomyocyte Proliferation: A New Model for the Study of Heart Regeneration.
    Ye L; Wang S; Xiao Y; Jiang C; Huang Y; Chen H; Zhang H; Zhang H; Liu J; Xu Z; Hong H
    J Am Heart Assoc; 2020 Jun; 9(11):e015574. PubMed ID: 32475201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload.
    Tykvartova T; Miklovic M; Kotrc M; Skaroupkova P; Kazdova L; Trnovska J; Skop V; Kolar M; Novotny J; Melenovsky V
    Pharmacol Res Perspect; 2024 Feb; 12(1):e1172. PubMed ID: 38284173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectively inhibiting PDE5: a novel therapeutic target for reversing cardiac remodeling in heart failure.
    Wang J; Wu X; Hu X; Jiang H
    Int J Cardiol; 2015 Jan; 178():210-1. PubMed ID: 25464255
    [No Abstract]   [Full Text] [Related]  

  • 20. Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia.
    Li S; Xin Q; Yan Y; Wang X; Ai H; Que B; Gong W; Nie S
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):81-91. PubMed ID: 38030140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.